X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-showcase-rapidly-expanding-oncology-pipeline-and-advances-in-current-product-portfolio-at-asco-2023-301809003.html
https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-secures-eight-additional-provincial
https://www.fiercepharma.com/manufacturing/tevas-halt-production-troubled-plant-seen-create-shortages-range-injectables
https://www.expresspharma.in/bdr-pharmaceuticals-launches-indias-first-generic-midostaurin-mstarin-to-treat-leukemia/
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-approval-of-additional-indication-for-vyxeos-daunorubicin-and-cytarabine-for-the-treatment-of-secondary-acute-myeloid-leukemia-in-pediatric-patients-301259059.html
http://www.pharmatimes.com/news/final_nice_green_light_for_pfizers_mylotarg_1260417
https://www.pharmaceutical-technology.com/news/company-news/nice-jazz-pharmaceuticals-vyxeos/
https://www.biospectrumasia.com/news/25/12036/-nice-recommends-vyxeos-for-specific-secondary-aml.html
http://www.prnewswire.co.uk/news-releases/vyxeos-receives-marketing-authorisation-in-the-european-union-for-treatment-of-certain-types-of-high-691777661.html
https://www.fiercepharma.com/marketing/waiting-green-light-jazz-staffs-up-for-excessive-sleep-treatment-and-vyxeos-push-europe
https://www.prnewswire.com/news-releases/journal-of-clinical-oncology-publishes-pivotal-phase-3-data-for-jazz-pharmaceuticals-vyxeos-daunorubicin-and-cytarabine-liposome-for-injection-849583154.html
http://www.pharmatimes.com/news/car-t_therapies_leap_towards_eu_approval_1242660
https://www.biospace.com/article/price-of-teva-s-generic-drug-to-treat-wilson-s-disease-sparks-outrage/
https://www.biospace.com/article/european-regulators-make-decisions-on-several-companies-drugs/
https://www.prnewswire.com/news-releases/national-comprehensive-cancer-network-adds-jazz-pharmaceuticals-vyxeos-daunorubicin-and-cytarabine-liposome-for-injection-to-clinical-practice-guidelines-in-oncology-300596110.html
http://www.pharmatimes.com/news/speedy_review_for_jazz_high-risk_aml_chemo_1210651
http://www.fiercepharma.com/regulatory/years-after-accelerated-approval-debacle-fda-panel-backs-pfizer-s-mylotarg
http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-acceptance-of-nda-for-vyxeos-cpx-351-an-investigational-treatment-for-acute-myeloid-leukemia-with-priority-review-status-300466520.html
http://www.prnewswire.com/news-releases/diplomat-now-dispensing-rydapt-midostaurin-for-acute-myeloid-leukemia-300460388.html
http://www.thepharmatimes.in/index.php/extras/jstuff/content-views/category-list-view/3906-sayre-therapeutics-announces-daunoxome-liposomal-daunorubicin-named-patient-program-in-india-and-select-saarc-markets-with-galen-limited-uk
http://www.prnewswire.com/news-releases/celator-pharmaceuticals-presented-phase-3-trial-results-in-patients-with-high-risk-acute-myeloid-leukemia-demonstrating-vyxeos-cpx-351-significantly-improved-overall-survival-300279899.html
http://www.prnewswire.com/news-releases/celator-pharmaceuticals-announces-positive-data-for-vyxeos-in-flt3-itd-mutated-acute-myeloid-leukemia-aml-cells-derived-from-patients-with-newly-diagnosed-aml-300252809.html
http://www.prnewswire.com/news-releases/celator-announces-phase-3-trial-for-vyxeos-cpx-351-in-patients-with-high-risk-acute-myeloid-leukemia-demonstrates-statistically-significant-improvement-in-overall-survival-300235620.html
http://www.prnewswire.com/news-releases/celator-pharmaceuticals-announces-participation-in-cardiff-university-clinical-trial-in-adults-with-acute-myeloid-leukemia-or-high-risk-myelodysplastic-syndrome-aml19-300202001.html
Market Place
Share 
